Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients

BACKGROUND: Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug–drug interactions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched their ART to bictegravir/emtricitabine/tenofovir alafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Schafer, Jason J, Pandit, Neha S, Cha, Agnes, Huesgen, Emily, Badowski, Melissa, Sherman, Elizabeth M, Cocohoba, Jennifer, Shimada, Ayako, Keith, Scott W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813207/
https://www.ncbi.nlm.nih.gov/pubmed/33511239
http://dx.doi.org/10.1093/ofid/ofaa625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813207/
https://www.ncbi.nlm.nih.gov/pubmed/33511239
http://dx.doi.org/10.1093/ofid/ofaa625

Ejemplares similares